Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis

Tianhua Xu, Yiting Sun, Wei Sun, Li Yao, Li Sun, Linlin Liu, Jianfei Ma, Lining Wang, Tianhua Xu, Yiting Sun, Wei Sun, Li Yao, Li Sun, Linlin Liu, Jianfei Ma, Lining Wang

Abstract

Omega-3 fatty acids (O3FAs) are associated with lower cardiovascular disease (CVD) risk in adults. However, this association in patients with end-stage renal disease (ESRD) remains controversial prompting the need for investigation into the role of O3FAs on serum lipids and vascular inflammation markers. The present meta-analysis summarized the effects of O3FA supplementation on serum lipids and vascular inflammatory markers in patients with ESRD. PubMed, EmBase, and the Cochrane Library were searched to identify randomized controlled trials (RCTs) focused on serum lipids and vascular inflammation markers in patients with ESRD. Standard mean differences (SMD) were used to measure the effect of O3FA supplementation on serum lipids and vascular inflammatory markers. The final pooled analysis included 20 RCTs involving 1,461 patients with ESRD. The results indicated that O3FA supplementation reduced TG by 0.61, LDL by 0.35 and CRP by 0.56. However, O3FA had no significant effect on TC, HDL, albumin, hemoglobin, homocysteine, DBP, glucose, lipoprotein(a), and ferritin. O3FA supplementation is associated with lower several serum lipids and vascular inflammation markers in patients with ESRD.

Figures

Figure 1. Flow diagram of the literature…
Figure 1. Flow diagram of the literature search and trials selection process.
Figure 2
Figure 2
Mean changes in triglyceride (A) and total cholesterol (B) based on O3FA supplementation.
Figure 3
Figure 3
Mean changes in LDL (A) and HDL (B) based on omega-3 fatty acid supplementation.
Figure 4
Figure 4
Mean changes in CRP (A), albumin (B), and hemoglobin (C) based on omega-3 fatty acid supplementation.
Figure 5
Figure 5
Mean changes in homocysteine (A), SBP (B), DBP (C), glucose (D), lipoprotein(a) (E), and ferritin (F) based on O3FA supplementation.
Figure 6. Funnel plot for TG, TC,…
Figure 6. Funnel plot for TG, TC, LDL, and HDL.

References

    1. Giray B., Kan E., Bali M., Hincal F. & Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta 338, 91–98 (2003).
    1. Himmelfarb J. et al.. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 17, 296–304 (2007).
    1. Vernaglione L., Cristofano C. & Chimienti S. Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: a prospective cohort study. Journal of nephrology 21, 99 (2008).
    1. Hu F. B. et al.. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287, 1815–1821 (2002).
    1. Benito P. et al.. Effects of milk enriched with ω-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clin Nutr 25, 581–587 (2006).
    1. Nóbrega O. T. et al.. Usual dietary intake and cardiovascular risk factors in older Brazilian women. Aging Clin Exp Res 24, 669–674 (2012).
    1. Baronzio G. et al.. Omega-3 fatty acids can improve radioresponse modifying tumor interstitial pressure, blood rheology and membrane peroxidability. Anticancer Res 14, 1145–1154 (1993).
    1. Avula C. R., Lawrence R. A., Jolly C. A. & Fernandes G. Role of n-3 polyunsaturated fatty acids (PUFA) in autoimmunity, inflammation, carcinogenesis, and apoptosis. Recent research developments in lipids 4, 303–319 (2000).
    1. Troyer D. & Fernandes G. Nutrition and apoptosis. Nutrition Research 16, 1959–1987 (1996).
    1. Chi H. et al.. Omega-3 Fatty Acid Supplementation on Lipid Profiles in Dialysis Patients: Meta-analysis. Arch Med Res 45, 469–477 (2014).
    1. Daud Z. A. M. et al.. Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients. Vascular health and risk management 8, 187 (2012).
    1. Kooshki A., Taleban F. A., Tabibi H. & Hedayati M. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Ren Fail 33, 892–898 (2011).
    1. Bouzidi N. et al.. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia. J Ren Nutr 20, 321–328 (2010).
    1. Khalatbari Soltani S. et al.. Effects of flaxseed consumption on systemic inflammation and serum lipid profile in hemodialysis patients with lipid abnormalities. Hemodialysis International 17, 275–281 (2013).
    1. Ando M., Sanaka T. & Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 10, 2177–2184 (1999).
    1. Khosroshahi H. T. et al.. Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iran J Kidney Dis 7, 479 (2013).
    1. Rasmussen L. E., Jørgensen K. A., Schmidt E. B. & Christensen J. H. The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease. Nutrition research 30, 535–540 (2010).
    1. Bowden R. G., Jitomir J., Wilson R. L. & Gentile M. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients. J Ren Nutr 19, 259–266 (2009).
    1. Lok C. E. et al.. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA 307, 1809–1816 (2012).
    1. Lemos J. R., de Alencastro M. G., Konrath A. V., Cargnin M. & Manfro R. C. Flaxseed oil supplementation decreases C-reactive protein levels in chronic hemodialysis patients. Nutrition Research 32, 921–927 (2012).
    1. Beavers K. M., Beavers D. P., Bowden R. G., Wilson R. L. & Gentile M. Omega‐3 fatty acid supplementation and total homocysteine levels in end‐stage renal disease patients. Nephrology 13, 284–288 (2008).
    1. Schmidt E. B., Jørgensen K. A. & Christensen J. H. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrology Dialysis Transplantation 23, 2918–2924 (2008).
    1. Christensen J. H., Sølling J. & Schmidt E. B. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am J Kidney Dis 44, 77–83 (2004).
    1. Taziki O., Lessan-Pezeshki M., Akha O. & Vasheghani F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transpl 18, 571 (2007).
    1. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr 10, 191–195 (2000).
    1. Chang J. W. et al.. Effects of α-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol 27, 70–74 (2007).
    1. Lee S. M., Son Y. K., Kim S. E. & An W. S. The effects of omega-3 Fatty Acid on vitamin d activation in hemodialysis patients: a pilot study. Mar Drugs 13, 741–755 (2015).
    1. Saifullah A. et al.. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients—a pilot study. Nephrology Dialysis Transplantation 22, 3561–3567 (2007).
    1. Madsen T., Schmidt E. B. & Christensen J. H. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. J Ren Nutr 17, 258–263 (2007).
    1. Beavers K. M., Beavers D. P., Bowden R. G., Wilson R. L. & Gentile M. Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population. J Ren Nutr 19, 443–449 (2009).
    1. Gharekhani A. et al.. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 70, 655–665 (2014).
    1. Hung A. M. et al.. Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrol Dial Transplant 30, 266–274 (2015).
    1. Naini A. E., Keyvandarian N., Mortazavi M., Taheri S. & Hosseini S. M. Effect of Omega-3 fatty acids on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patients. J Res Pharm Pract 4, 135–41 (2015).
    1. Jadad A. R. et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1–12 (1996).
    1. Rizos E. C., Ntzani E. E., Bika E., Kostapanos M. S. & Elisaf M. S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308, 1024–33 (2012).
    1. Casula M., Soranna D., Catapano A. L. & Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl 14, 243–51 (2013).
    1. Fiedler R., Mall M., Wand C. & Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr 15, 253–256 (2005).
    1. Bowden R. G., Wilson R. L., Deike E. & Gentile M. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 24, 508–512 (2009).
    1. Abeywardena M. Y. & Belobrajdic D. P. Long-Chain Omega-3 Polyunsaturated Fatty Acids and Obesity. Obesity. Springer International Publishing pp 29–44 (2016).
    1. Moher D., Liberati A., Tetzlaff J. & Altman D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151, 264–269 (2009).
    1. DerSimonian R. & Laird N. Meta-analysis in clinical trials. Control Clin Trials 7, 177–188 (1986).
    1. Ades A., Lu G. & Higgins J. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 25, 646–654 (2005).
    1. Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull 47, 15–17 (1999).
    1. Higgins J. P., Thompson S. G., Deeks J. J. & Altman D. G. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal 327, 557 (2003).
    1. Deeks J. J., Higgins J. & Altman D. G. Analysing Data and Undertaking Meta‐Analyses. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series 243–296 (2008).
    1. Deeks J. J., Altman D. G. & Bradburn M. J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Egger M., Davey Smith G., Altman D. G. eds Systematic Reviews in Health Care: Metaanalysis in Context. 2nd ed. London: BMJ Books, 285–312 (2001).
    1. Egger M., Smith G. D., Schneider M. & Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 (1997).
    1. Begg C. B. & Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1088–1101 (1994).
    1. Duvall S. & Tweedie R. A nonparametric “trim and fill” method for assessing publication bias in meta-analysis. J Am Stat Assoc 95, 89–98 (2000).

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit